Second, PARP-1 mRNA was overexpressed in T2DM patients (Adaikalakoteswari et al., 2007), and PARP inhibition protected cardiomyocytes from endothelium dysfunction (Choi et al., 2012; Zakaria et al., 2016), glucose stimulation (Choi et al., 2012; Qin et al., 2016b), and apoptosis (Qin et al., 2016b) in mice with T2DM or diabetic cardiomyopathy. Here, PARP1 is linked to type 2 diabetes mellitus.